An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany
Authors:
- 15 July 2016
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 17 (1) , 85-98
Abstract
Introduction: Since 2007, the German Standing Vaccination Committee recommends HPV vaccination for girls aged 12–17 with a 2- (Cervarix®) or 4-valent (Gardasil®) vaccine. A 9-valent vaccine (Gardasil 9®) recently received a European market authorization in 2015. Methods: A dynamic transmission model was calibrated to the German setting and used to estimate costs and QALYs associated with vaccination strategies. Results: Compared to the current vaccination program, the 9-valent vaccine extended to boys shows further reductions of 24% in the incidence of cervical cancer, 30% and 14% in anal cancer for males and females, as well as over a million cases of genital warts avoided after 100 years. The new strategy is associated with an ICER of 22,987€ per QALY gained, decreasing to 329€ when considering the vaccine switch for girls-only. Conclusion: Universal vaccination with the 9-valent vaccine can yield significant health benefits when compared to the current program.Keywords
Funding Information
- Sanofi Pasteur MSD
This publication has 51 references indexed in Scilit:
- Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84 – results of WOLVES, a population-based epidemiological study in Wolfsburg, GermanyBMC Infectious Diseases, 2013
- Prevalence of low-risk HPV types and genital warts in women born 1988/89 or 1983/84 -results of WOLVES, a population-based epidemiological study in Wolfsburg, GermanyBMC Infectious Diseases, 2012
- Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a reviewBMC Cancer, 2012
- HPV Vaccine against Anal HPV Infection and Anal Intraepithelial NeoplasiaNew England Journal of Medicine, 2011
- Economic burden of vulvar and vaginal intraepithelial neoplasia: retrospective cost study at a German dysplasia centreBMC Infectious Diseases, 2011
- Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in MalesNew England Journal of Medicine, 2011
- Incidence of anogenital warts in Germany: a population-based cohort studyBMC Infectious Diseases, 2010
- Impact of vaccinating boys and men against HPV in the United StatesVaccine, 2010
- Estimation of the incidence of genital warts and the cost of illness in Germany: A cross-sectional studyBMC Infectious Diseases, 2008
- The economic burden of noncervical human papillomavirus disease in the United StatesAmerican Journal of Obstetrics and Gynecology, 2008